HPC
PHAT icon

HM Payson & Co’s Phathom Pharmaceuticals PHAT Stock Holding History

HM Payson & Co’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-111
Closed -$2K – 1122
2021
Q4 		$2K Buy
+111
New +$2.61K ﹤0.01% 1017
2021
Q2 		– Sell
-365
Closed -$14K – 1144
2021
Q1 		$14K Buy
+365
New +$15.3K ﹤0.01% 831

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

HM Payson & Co's PHAT Position: Q1 2022 in Review

HM Payson & Co sold out of Phathom Pharmaceuticals (PHAT) in Q1 2022, closing a stake of 111 shares — an estimated $2K sold.

HM Payson & Co first reported a position in PHAT in Q1 2021 and held it in 2 quarters. The position peaked at $14K in Q1 2021. 82 funds tracked by Wall St. Rank hold PHAT as of Q1 2022.

  • HM Payson & Co reported no remaining Phathom Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • HM Payson & Co sold 111 Phathom Pharmaceuticals shares in Q1 2022, an estimated $2K.
  • HM Payson & Co first reported a position in Phathom Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • HM Payson & Co's Phathom Pharmaceuticals position peaked at $14K in Q1 2021.
  • 82 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2022.

Based on HM Payson & Co's 13F filing for Q1 2022, filed 12 May 2022.